Amgen settles with FTC over US$28 billion deal
Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products
Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Sets price band at ?695 to ?735 per Equity Share
Granules India received approval from Brazilian Health Regulatory Agency ANVISA
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
Mizoram appoints Youth for Action as the Interfacing Agency for implementing the ABDM Microsite in Aizawl
Eris Lifesciences enters into term loan agreement with Citi Bank
The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million
Subscribe To Our Newsletter & Stay Updated